

IN THE CLAIMS

Claim 1 (original): A blood plasma for human use pooled from donors which belong to 10 % or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing blood or blood plasma of blood group 0 characterized in that

- five to six parts of blood or blood plasma from donors having the blood group A,
- four parts to five parts of blood or blood plasma from donors having the blood group B,
- zero to one part of blood or blood plasma from donors having the blood group AB.

Claim 2 (original): The blood plasma according to claim 1 virus-inactivated by any virus inactivation or virus removal method.

Claim 3 (original): The blood plasma according to claim 2 wherein the blood plasma was inactivated by solvent/detergent treatment, irradiation, pasteurisation and/or nanofiltration.

Claim 4 (original): The blood plasma according to claim 3 wherein the virus inactivation was performed by using detergents such as oxyethylated polyphenols, like Triton-X-100, and/or polyoxyethylene derivatives of fatty acids such as Tween 80 and tri-N-butylphosphate (TNBP), or combinations thereof.

Claim 5 (original): The blood plasma according to claim 3 virus inactivated by treatment with long-chain fatty acids, such as

caprylic acid or the respective salts.

Claim 6 (currently amended): The blood plasma according to ~~any of the foregoing claims~~ claim 1 substantially free of virus inactivating agents.

Claim 7 (currently amended): The blood plasma of ~~any one of the foregoing claims~~ claim 1 having ABO blood group specific antibody titre lower than 16 for anti-A and anti-B IgM antibodies, and lower than 64 for anti-A and anti-B IgG antibodies.

Claim 8 (currently amended): The blood plasma of ~~any one of the foregoing claims~~ claim 1 in liquid, frozen, dried, or lyophilised form.

Claim 9 (currently amended): A pharmaceutical composition comprising the blood plasma of ~~any one of the claims 1 to 8~~ claim 1.

Claim 10 (currently amended): Use of the blood plasma of ~~any one of the foregoing claims~~ claim 1 for the manufacturing of a medicament for the treatment of coagulation factor deficiencies, thrombotic purpura, and in repeated large volume plasma exchange.

Claim 11 (currently amended): A process for manufacturing the blood plasma of ~~any one of the claims 1 to 8~~ claim 1 by admixing

- four to eight parts of blood or blood plasma from donors having the blood group A,

- more than three parts to seven parts of blood or blood plasma from donors having the blood group B,
- zero to two parts of blood or blood plasma from donors having the blood group AB.